Alera Bio Launches Newly Redesigned Website to Advance Awareness and Support for Rare Neurological Diseases

Chicago, IL - November 14, 2025 - Alera Bio, a biotechnology company committed to developing innovative therapies for patients with rare neurological and neuroendocrine disorders, today announced the launch of its newly redesigned website, **www.alerabio.com**.

The new site offers an enhanced user experience, a clean and modern design, and expanded content that highlights Alera Bio's scientific mission and dedication to the patient community.

Key features of the new website include:

- **Pipeline Overview:** Detailed information on Alera Bio's lead program, AB-101, a novel therapeutic candidate for MCT-8 deficiency, a devastating rare neurological disorder with no approved treatments.
- **Patient and Caregiver Resources:** Tools and educational materials designed to support families navigating the complexities of rare diseases.
- **Company Vision and Mission:** A clear articulation of Alera Bio's belief that *biology drives us and patients define us*, reinforced through the new design and content structure.

"The launch of our new website represents an important milestone in Alera Bio's growth," said Philip Vorhies, CEO of Alera Bio. "Our goal was to create a central hub where patients, caregivers, and partners can learn about our progress and our mission to bring hope through science."

The redesigned site also reflects Alera Bio's broader strategy to increase transparency, accessibility, and engagement with the rare disease community, while serving as a platform for future updates on clinical progress, partnerships, and advocacy initiatives.

To explore the new site and learn more about Alera Bio's work in advancing therapies for rare neurological disorders, visit **www.alerabio.com**.

Advancing Rare Disease Innovation

Alera Bio is developing AB-101, its lead program in MCT-8 deficiency (Allan-Herndon-Dudley Syndrome), a devastating rare neurological disorder with no approved therapies. AB-101 has received FDA Rare Pediatric Disease designation, underscoring the medical urgency and the company's opportunity to accelerate its path toward patients.

About Alera Bio

Alera Bio is a privately held biotechnology company dedicated to developing transformative therapies for rare and neglected neurological diseases. Headquartered in Chicago, IL, the company was founded in 2025 with a singular goal: to improve the lives of patients suffering from devastating neurological deficits.

Its lead program, AB-101 for MCT-8 deficiency, has been granted FDA Rare Pediatric Disease designation, highlighting both the urgency of this patient population and the potential for expedited development.

Guided by a patient-first strategy, Alera Bio combines cutting-edge science with a capital-efficient development model to address critical unmet needs. The company's approach focuses on restoring biological function, advancing therapies that target both neurological and systemic pathways, and working collaboratively with families, researchers, and regulators to accelerate meaningful solutions.

At Alera Bio, our mission is clear: Biology drives us. Patients define us.